Form D · Biotechnology

Spero Therapeutics, Inc.

Cambridge, MA · CIK 0001701108

Offering snapshot reported Nov 15, 2022 · SEC filing

Reported sold
$9M
Offering amount: $9M
Investors reported
1
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Nov 7, 2022
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Nov 15, 2022Initial$9,000,000No comparison1SEC filing
Jul 14, 2021Initial$39,999,985No comparisonNot reportedSEC filing
Mar 21, 2017Initial$43,177,051No comparison11SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-464777

Source: Form D, filed Nov 15, 2022. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Casper Breum Director
Milind Deshpande Director
Jean Francois Formela Director
Stephen Garbacz Executive
Vikas Goyal Director
Reza Halse Director
Kamal Hamed Executive
Scott Jackson Director
Tamara Joseph Executive
Timothy Keutzer Executive
Cristina Larkin Executive
Ankit Mahadevia Director, Executive
David Melnick Executive
John C. Pottage, Jr. Director
Satyavrat Shukla Executive
Cynthia Smith Director
Frank E. Thomas Director
Kathleen Tregoning Director
Patrick Vink Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
675 Massachusetts Avenue 14 Th Floor
Cambridge, MA, 02139